Public Summary Documents by Meeting
PBAC Public Summary Documents - November 2006
Public summary documents relating to the November 2006 PBAC meeting
Adalimumab, injection, 40 mg in 0.8 mL pre-filled syringe, Humira®
Anecortave Acetate, depot suspension, 15 mg in 0.5 ml, Retaane®
Atomoxetine Hydrochloride, capsules, 10 mg, 18 mg, 25 mg, 40 mg and 60 mg,
Strattera®
Bortezomib, powder for I.V. injection, 3.5 mg,Velcade®
Docetaxel, injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL and 1 single use vial solvent 1.5 mL and injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL and 1 single use vial solvent 6 mL, Taxotere®
Erlotinib hydrochloride, film-coated tablets, 25 mg, 100 mg and 150 mg (base), Tarceva®
Ezetimibe, tablet, 10 mg, Ezetrol®, and Ezetimibe with Simvastatin, tablet, 10 mg – 10 mg, 10 mg – 40 mg and 10 mg – 80 mg, Vytorin®
Famciclovir, Tablet, 500 mg, Famvir®
Human Rotavirus Vaccine, lyophilised powder and solvent for oral administration, one mL dose, Rotarix®
Methylphenidate Hydrochloride, extended release tablets, 18 mg, 36 mg and 54 mg, Concerta®
Natalizumab, concentrated solution for IV infusion, 300 mg per 15 mL, Tysabri®
Pegfilgrastrim, injection 6 mg in 0.6 mL single use prefilled syringe and injection 6 mg in 0.6 mL single use prefilled pen, Neulasta® and Neulasta Sureclick®
Pramipexole Hydrochloride, tablet, 125 micrograms and 250 micrograms, Sifrol®
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) recombinant vaccine, injection, 0.5 mL, Gardasil®
Risperidone, tablet, 500 microgram, 1 mg, 2 mg, oral solution 1 mg per mL, Risperdal®, oral disintegrating tablet, 500 microgram, 1 mg, 2 mg, Risperdal®Quicklet®
Rotavirus vaccine, live, oral liquid, pentavalent, 2 mL unit dose RotaTeq®
Sevelamer Hydrochloride, tablet, 800 mg, Renagel®
Sibutramine hydrochloride, capsules, 10 mg and 15 mg, Reductil/Ectiva®
Sildenafil Citrate, tablet, 20 mg, Revatio®
Somatropin, powder for injection and diluent, 5 mg per mL, 12 mg per mL (with preservative), powder for injection and diluent (single dose syringes) in strengths from 0.8 mg – 2 mg per 0.25 mL, Genotropin® and Genotropin MiniQuick®
Sorafenib Tosylate, tablet, 200 mg (base), Nexavar®
Strontium Ranelate, sachet containing granules for oral suspension, 2 g, Protos®
Trandolapril with Verapamil Hydrochloride-SR, film-coated tablet, 4 mg – 240 mg (sustained release), Tarka®
Triptorelin Embonate, powder for injection and 1 vial solvent 2 mL, 3.75 mg (1 month) and 11.25 mg (3 month) (base), Diphereline®
Ziprasidone Hydrochloride, capsules, 20 mg, 40 mg, 60 mg, 80 mg, Zeldox®
Independent Review Report for Teriparatide
Sponsor's response to Independent Review Report for Teriparatide
Teriparatide, solution for injection, in a 3 mL cartridge contained in a pre-filled disposable delivery device (pen), 250 micrograms in 1 mL, Forteo®
